Premium
Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation ( JSHCT )
Author(s) -
Konuma Takaaki,
Yanada Masamitsu,
Yamasaki Satoshi,
Kuwatsuka Yachiyo,
Fukuda Takahiro,
Kobayashi Takeshi,
Ozawa Yukiyasu,
Uchida Naoyuki,
Ota Shuichi,
Hoshino Takumi,
Takahashi Satoshi,
Kanda Yoshinobu,
Ueda Yasunori,
Takanashi Minoko,
Kanda Junya,
Ichinohe Tatsuo,
Atsuta Yoshiko,
Yano Shingo
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15399
Subject(s) - medicine , transplantation , haematopoiesis , myeloid leukaemia , cumulative incidence , myeloid leukemia , oncology , incidence (geometry) , myeloid , multivariate analysis , leukemia , hematopoietic cell , hematology , immunology , stem cell , biology , genetics , physics , optics
Summary To evaluate the outcomes and prognostic factors following allogeneic haematopoietic cell transplantation ( HCT ) for adult acute myeloid leukaemia ( AML ) in second complete remission ( CR 2), we retrospectively analysed the Japanese registration data of 1080 adult AML patients in CR 2 who had received allogeneic HCT . The probability of overall survival and the cumulative incidence of relapse at 3 years was 66% and 19%, respectively. In multivariate analysis, older age, poor cytogenetics and shorter duration of first complete remission were significantly associated with a higher overall mortality. Our data demonstrated the significant efficacy of allogeneic HCT for adult AML in CR 2.